Skip to main content
ABVC BIOPHARMA, INC. logo

ABVC BIOPHARMA, INC. — Investor Relations & Filings

Ticker · ABVC ISIN · US00091F1066 US Manufacturing
Open in API
Filings indexed 780 across all filing types
Latest filing 2022-06-21 Regulatory Filings
Country US United States of America
Listing US ABVC

About ABVC BIOPHARMA, INC.

https://abvcpharma.com/

ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company that develops and commercializes drugs and medical devices to address unmet medical needs. The company focuses on advancing a pipeline of botanical, plant-based pharmaceuticals and medical technologies sourced from research institutions. Its therapeutic areas of focus include oncology, ophthalmology, and central nervous system disorders such as major depressive disorder (MDD) and adult attention-deficit/hyperactivity disorder (ADHD). Key products in development include Vitargus®, a biodegradable vitreous substitute for eye surgery, and botanical drug candidates for MDD and ADHD. Additionally, its subsidiary, BioKey, Inc., offers contract development and manufacturing services for nutritional and pharmaceutical products.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2022
Regulatory Filings
2022-06-21 English
POST-EFFECTIVE AMENDMENT NO. 2 TO FORM S-1
Capital/Financing Update Classification · 95% confidence The document is a Form S-1 Registration Statement filed with the SEC, specifically a Post-Effective Amendment No. 2 to a previously declared effective Form S-1. It includes a preliminary prospectus for the resale of shares by selling stockholders. The document references registration under the Securities Act of 1933 and discusses the offering of securities, selling stockholders, and related disclosures. This type of filing is related to capital raising and securities registration rather than financial reporting, management changes, or other categories. Therefore, it fits the Capital/Financing Update category (CAP). The document is substantial in length (15,000 characters) and contains detailed offering information, not just an announcement or a brief notice, so it is not an RPA or RNS. Hence, the classification is CAP with high confidence.
2022-06-14 English
POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-1
Capital/Financing Update Classification · 95% confidence The document is a Post-Effective Amendment No. 1 to a Registration Statement on Form S-1 filed with the SEC by ABVC Biopharma, Inc. It is related to the registration of shares underlying previously issued warrants. The document includes a preliminary prospectus, detailed offering information, risk factors, management discussion and analysis, business description, management and executive compensation, and other typical sections of a registration statement prospectus. The Form S-1 and its amendments are filings related to securities registration for public offerings, which fall under capital raising activities. This is not an annual report, earnings release, or other financial report but a capital/financing update related to securities registration and offering. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains the full registration statement amendment, not just an announcement or certification, supporting a high confidence in classification.
2022-06-14 English
AMENDED CURRENT REPORT
Board/Management Information Classification · 100% confidence The document is a Form 8-K/A filed with the SEC, which is an amendment to a current report. The content specifically announces the departure of a director due to passing and the appointment of a new director to fill the vacancy. This is a clear announcement of changes in the company's board of directors. There is no financial data or report attached, and the document is relatively short (3717 characters). Therefore, it fits the category of Board/Management Information (MANG).
2022-06-09 English
AMENDMENT NO. 1 TO FORM 10-K
Annual Report FY 2021
2022-06-06 English
CURRENT REPORT
Board/Management Information Classification · 100% confidence The document is a Form 8-K Current Report filed with the SEC, dated May 27, 2022. The key content is the announcement of the departure of a director due to death, with mention of searching for a replacement. There are no financial statements or detailed financial data, nor is this a full annual or quarterly report. The primary subject is a change in the company's board of directors. According to the filing definitions, announcements of changes in the company's board of directors or senior management fall under Board/Management Information (MANG). The document length is short (2842 characters), and it is not an announcement of a report publication or a certification. Therefore, the correct classification is MANG with high confidence.
2022-06-01 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.